Function and regulation of gastrin in transgenic mice: a review. by Wang, T. C. & Brand, S. J.
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 65 (1992), 705-713
Function and Regulation ofGastrin in Transgenic Mice:
A Review
TIMOTHY C. WANG, M.D., AND STEPHEN J. BRAND, M.D., Ph.D.
Gastrointestinal Unit, DepartmentofMedicine, Massachusetts GeneralHospital,
Boston, Massachusetts
Received July 6, 1992
The gastrin gene is expressed in fetal pancreatic islet cells, but in the adult is expressed
mainlyin thegastric antrum. Tostudythe regulation ofthegastrin promoter,we created several
transgenes containing the human and rat gastrin 5' flanking regions joined to the coding
sequences of the human gastrin gene. The human gastrin transgene contained 1,300 bp of 5'
flankingDNA, while the ratgastrin transgene contained 450bpof5' flanking DNA. The human
gastrin transgene was expressed in fetal islets, butwas not expressed in adult gastric antrum. In
contrast, the rat gastrin transgene was expressed in adult antral G cells, but no expression was
observed in fetal islets. To study the possible role ofgastrin as an islet growth factor, a chimeric
insulin-gastrin (INS-GAS) transgene was created, in which the expression ofthe human gastrin
gene is driven from the rat insulin I promoter. These INS-GAS mice were mated with mice
overexpressing TGFa, transcribed from a mouse metallothionein-transforming growth factora
(MT-TGFa) transgene. While overexpression ofgastrin or TGFa alone had no effect on islet
mass, overexpression of both transgenes resulted in a twofold increase in islet mass. In
conclusion, these data indicate that (1) gastrin can interact synergistically with TGFa to
stimulate islet growth; (2) the human gastrin transgene contains the islet specific enhancer; (3)
the rat gastrin transgene contains the antral specific enhancer.
The gastrin gene exhibits a complex pattern of tissue specificity and temporal
regulation during development. In the adult rat organism, the major site of expres-
sion is in the gastric antrum, where gastrin functions as a regulatory peptide with at
least several functions: (1) a hormone controlling acid secretion and (2) a growth
factor stimulating mucosal proliferation [1,2]. The expression of gastrin mRNA in
the gastric antrum does not begin until after birth, and then rises to achieve adult
levels between postnatal days 10 and 20. In the antrum, gastrin is found localized to
an endocrine cell population, known as G cells, where the gene is regulated by
luminal contents, and by changes in gastric pH through modulating paracrine
inhibition by somatostatin [3].
In contrast, in the rat fetus, the pancreas is the major site of gastrin gene
expression. The highest levels ofpancreaticgastrin mRNA are seen in the day 18 rat
fetus [4]. After birth, pancreatic gastrin mRNA levels decline rapidly at the same
time that other islet mRNAs (insulin, glucagon, somatostatin) achieve stable,
maximal levels. By the third postnatal day, pancreatic gastrin mRNA levels are
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undetectable. Until recently, however, the function of fetal pancreatic gastrin gene
expression has remained unclear.
A number ofprevious observations suggest that gastrin may regulate the growth of
pancreatic islets during development. The transient expression of gastrin in the
neonatal pancreas corresponds to a period of rapid pancreatic growth. During this
period, committed islet-cell precursors proliferate by budding from pancreatic ducts,
and then differentiate into mature islet cells [5]. After birth, islet development
dramatically decreases, and gastrin expression is also repressed. Furthermore, some
clinical observations support such a role. Hypergastrinemia is associated with
nesidioblastosis, and an abnormal persistence of gastrin has been documented in a
case of infantile nesidioblastosis [6]. These reports did not, however, establish a
causal relationship between nesidioblastosis and gastrin stimulation. Gastrin also
acts as an autocrine growth factor for gastrin-expressing islet tumor cells growing in
culture [Brand S: unpublished observations]. Nevertheless, studies demonstrating a
direct effect ofgastrin on islet growth in vivo have been lacking.
Furthermore, gastrin mRNA found in the antrum and the pancreas have identical
initiation sites, indicating that they are transcribed from the same promoter [4]. This
fact suggests that the developmental regulation of gastrin is controlled by a complex
transcriptional mechanism. Studies examining the regulation ofgastrin gene transcrip-
tion were initially based on cell transfection systems, using human gastrin promoter-
reporter gene constructs. Theill et al. examined human gastrin promoter activity in
neuroblastoma cells, and showed that important cis-regulatory control elements lay
downstream of the TATA box [7]. Merchant et al. reported that a human gastrin
reporter gene construct containing only 40 bp of 5' flanking DNA was sufficient for
basal transcription in GH4 pituitary cells [8].
More recently, through a series of deletions of the human gastrin promoter, we
defined a cis-regulatory domain, located between -108 and -76, which controlled
activity ofthe gastrin promoter in islet cells [9]. This domain in the gastrin promoter
contained a negative element (ATTCCTCT), also found in the promoters ofthe beta
interferon and the cytoactin genes, which inhibited transcription in islet cells.
Adjacent to the negative element was a positive element (CATATGG), which is
similar to cis-regulatory elements in the insulin promoter that determine islet-cell
specific transcription of the insulin gene. This latter finding suggests that the gastrin
gene may be activated by the same transcription factor that activates insulin
transcription in islet cells. Insulin gene transcription is activated by helix-loop-helix
(HLH) transcription factors binding to DNA sequences in the insulin promoter
containing the CANNTG motif, also known as theE box. Gastrin transcription in
islet cells is also regulated by HLH transcription factors, as demonstrated by
experiments using antibodies to the cloned E2/PAN HLH factors [10], which inhibit
binding of the islet nuclear proteins to the gastrin insulin enhancer-like element
(CATATGG). Thus, the organization of the islet enhancer, with its tandem array of
positive and negative elements, suggests a molecular switch, which might control the
transient expression of the gastrin gene during pancreatic development.
The regulatory sequences identified by the transfection of cultured cells in vitro are
not, however, always an accurate reflection of the mechanisms used in the whole
animal [11]. Furthermore, the cis-acting elements targeting antral-specific expres-
sion ofthe gastrin gene have not been identified. This omission has been due in part
to the lack of availability of a permanent gastrin-expressing antral G cell line.
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Therefore, to determine whether the islet-cell specific regulatory domains in this
promoter are fully functional in vivo, and to develop a murine model to study
transcriptional regulation of gastrin in adult stomach, transgenic mice containing a
variety of gastrin gene constructs were developed. This paper reviews a number of
recent transgenic studies examining the regulation and the function of gastrin in
transgenic mice. Further details ofthese studies will be published elsewhere [12,13].
EXPRESSION OF RAT AND HUMAN GASTRIN PROMOTER
CONSTRUCTS IN TRANSGENIC MICE
Initially, we made a transgene containing 450 bp of the rat gastrin promoter, plus
the first non-coding exon, joined to a reporter gene which consisted of the coding
portions of the human gastrin gene (Fig. 1). This rat gastrin (RAT-GAS) transgene
was cut with restriction enzymes to remove vector sequences, purified according to
standard procedures [14], and microinjected into fertilized mouse eggs. Three
founders were identified, two ofwhich expressed the transgene at significant levels,
as determined by Northern blot analysis [12]. Total RNA was isolated from the
gastric antrum and several other tissues, size fractionated by electrophoresis in
denaturing gels, transferred to nitrocellulose, and hybridized to a probe specific for
exon II of the human gastrin gene. Significant levels of a 950 nt RNA, which
co-migrated with the human gastrin-positive control, were observed in the gastric
antrum of two of the lines examined: RAT-GAS 1 and RAT-GAS 2; no expression
was seen in the third line, RAT-GAS 3. In the two expressing lines, no expression
was seen in the gastric corpus or in tissues examined outside the gastrointestinal
tract. Low levels of expression were, however, observed in the small intestine and
colon.
The highest expressing line, RAT-GAS 1, was analyzed in more detail. To confirm
that the expression of the RAT-GAS transgene seen in the gastric antrum was
cell-specific for G cells, in situ hybridization was performed on formalin-fixed,
paraffin-embedded sections, using a human gastrin exon II antisense riboprobe; in
addition, the sections were tested with the rodent-specific (rat) gastrin exon III
riboprobe inorder to examine expression ofthe endogenous mousegastrin gene [12].
Both the endogenous mouse gastrin gene and the transgene were expressed in G
cells located at the base of the crypts in the antrum, and expression of both was
extinguished sharply at the antral-corpus junction. While the endogenous mouse
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gastrin gene was also sharply extinguished at the pylorus, however, the transgene
demonstrated low levels of expression in the duodenum. The transgene therefore
demonstrated correct cell-specific expression in the antral G cells.
A further developmental profile was carried out, using the technique of in situ
hybridization [12]. To determine whether the RAT-GAS transgene was expressed in
fetal tissue, 19-day-old fetuses were removed from pregnant transgenicmice, fixed in
formalin, and embedded in paraffin. In situ hybridization was carried out with the
same human gastrin exon II probe. In the 19-day-old fetus, no expression was
detected in either the fetal pancreas or the fetal stomach. At three days postpartum,
the expression of the rat gastrin transgene was still absent, but expression was
detected at low levels in antral G cells. By ten days postpartum, expression in the
mouse antrum was present at much higher levels. Thus, the rat gastrin promoter
appeared to be correctly regulated developmentally in the gastric antrum, but not in
the fetal pancreas.
The human gastrin promoter was then examined in transgenic mice, using a
human gastrin minigene construct (Fig. 1). The human gastrin minigene contained
1.3 kb of human gastrin 5' flanking DNA plus the first (57 nt) non-coding exon,
joined to the coding exons of the human gastrin gene. Three founder human gastrin
(hGAS 1-3) transgenic lines were created, two of which (hGAS 1 and hGAS 2)
expressed human gastrin mRNA at high levels. In contrast to the tissue-specific
expression seen with the rat gastrin transgene, the human gastrin minigene was not
expressed in the gastric antrum, but instead demonstrated aberrant expression in the
adult liver. Northern blot analysis of RNA from both the hGAS 1 and hGAS 2
human gastrin minigene lines revealed that human gastrin mRNA was found in the
liver, but not in the gastric antrum, corpus, duodenum, small intestine, colon, or
pancreas. RNase protection studies revealed that transcription in both lines origi-
nated from the authenticgastrin promoter.
Since the Northern blot did not distinguish between hepatocyte and non-
hepatocyte expression, in situ hybridization was performed on the human gastrin
minigene lines at various stages of development [12]. In situ hybridization of
formalin-fixed tissue from day 18 fetal mice revealed that the expression could be
demonstrated at a high level in larger clusters of cells in the liver. At day 3
postpartum, the expression ofthe humangastrin transgene appeared tobe repressed
in the centrilobular region, which was even more prominent by day 10. By the adult
stage, expression was apparent in only a small proportion (1-2 percent) of hepato-
cytes.
The finding that the human gastrin promoter demonstrated liver-specific expres-
sion was unexpected. Although this finding may be simply an aberrancy due to
species difference between the human and rodent gastrin genes, it may also reflect
the close relationship developmentally between the liver and the pancreas. Both the
liver and the pancreas arise from an outpocketing offoregut endoderm. In addition,
rats can exhibit "transdifferentiation" ofpancreatic ductcells intohepatocytesunder
conditions of copper or methionine deficiency [15,16]. Therefore, there may exist a
primitive endodermal stem cell that has the capacity to differentiate into either liver
orpancreatic cell lineages, and repression ofgenes such asgastrin maybe part ofthe
normal differentiation process in the liver.
Finally, although the human gastrin minigene was not expressed in the adult
pancreas, expression was plainly evident in the fetal pancreas. A high level of
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FIG. 2. Messenger RNA expression patterns observed in transgenic
lines bearing either the rat gastrin transgene or the human gastrin
transgene. The expression pattern was determined by Northern blot
and/or in situ hybridization assays in one or more lines.
expression was clearly demonstrated in proliferating islet-cell precursors at day 18 of
fetal development. By day 3 postpartum, expression was present at low levels in the
islet cells; by day 10 postpartum, expression was completely absent from the
pancreas.
Thus, the human gastrin promoter, unlike the rat gastrin promoter, contains the
islet-cell specific enhancer that both activates transcription ofthe gastrin gene in the
pancreas, and represses transcription after birth. Previous transfection studies and
gel mobility shift assays suggested that islet-cell expression ofthe humangastrin gene
is controlled by a cis-regulatory domain between -108 and -76 bp upstream of the
start site [4]. This region ofthe humangastrin gene contains some homologywith the
corresponding region of the rat gastrin gene; however, there are also significant
differences. Further transgenic studieswill be required to confirm that this region of
the human gastrin promoter is responsible for regulating fetal islet expression. Such
studies have been performed with the alpha feto-protein (AFP) gene, which is
transiently expressed in the fetal liver but subsequently repressed after birth.
Transgenic studies have confirmed that a cis-acting negative regulatory element
(NRE) located 3.5 kb upstream is responsible forthe postnatal extinctionofthe AFP
transgene in liver cells [17]. A similar switch mechanism may be responsible for
repressing gastrin in the neonatal pancreas.
Figure 2 summarizes the differences in the patterns of expression of the rat and
human gastrin genes. The rat gastrin gene was expressed appropriately in the adult
gastric antrum, but was not expressed in the fetal pancreas (within the limits of
detection of our assay), and demonstrated inappropriate expression in the small
intestine and colon. In contrast, the human gastrin transgene was expressed in the
fetal pancreatic islets, but was not expressed in adult antrum, and demonstrated
inappropriate expression in fetal and adult liver. The results suggest a complex
pattern ofexpression that includes at least two different positive regulatory elements
(islet and antral), and at least two negative regulatory elements (liver and intestinal).
The absence of a correct pattern of transgene expression is, in most instances,
attributed to the absence of necessary cis-acting regulatory elements due to insuffi-
cient amounts of 5' flanking DNA. Furthermore, some of the differences between
the expression patterns of the rat and human transgenes may be due to different
lengths of promoter used; however, recent studies suggest that very different
mechanisms can be used to regulate gene expression in mouse and human species, or
between two different mouse species [18]. Future studies will be directed at further
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FIG. 3. Diagram ofthe insulin-gastrin transgene, which contained 370bpof5' flanking DNA
and the first non-coding exon of the rat insulin 1 gene, joined to the coding portion of the
human gastrin gene.
characterizing the cis-acting elements controlling these different patterns of tissue-
specific expression.
EFFECT OF SUSTAINED PANCREATIC GASTRIN EXPRESSION
IN TRANSGENIC MICE
The role ofgastrin as an islet growth factor was then examined in transgenic mice
expressing a chimeric insulin-gastrin (INS-GAS) transgene, in which the human
gastrin gene was transcribed from the rat insulin I promoter. Since the insulin
promoter continues to be highly transcribed after birth, this transgene will express
high levels ofgastrin in the pancreas after the endogenous gastrin is switched off. If
gastrin regulates islet growth, then enhanced islet growth might result from a
postnatal persistence ofpancreaticgastrin.
The insulin-gastrin transgene (INS-GAS) comprised 370 bp of 5' flanking DNA
and thefirstnon-coding exonofthe rat insulin I gene, ligated to the sequences (exons
II and III) ofthe humangene encoding thepre-progastrinpeptide precursor (Fig. 3).
The INS-GAS fragment was isolated and microinjected into inbred one-cell mouse
embryos. Three transgenic founder lines were generated. One of the three lines,
INS-GAS 1, highly expressed human gastrin mRNA [13]. A Northern blot of total
RNA isolated from the INS-GAS 1 line, probed with a human gastrin exon II
riboprobe, demonstrated expression in pancreatic tissue, but in none of the other
tissues examined, including stomach and small intestine. No gastrin mRNA was
observed in pancreatic RNA from non-transgenic FVB mice. The gastrin transgene
mRNA was efficiently translated into the bioactive gastrin peptide, since pancreatic
extracts contained high levels ofgastrin immunoreactivity, usinga radioimmunoassay
specific for bioactive C-terminal amidated gastrin. Immunohistochemistry showed
gastrin was expressed only in the pancreatic islets; no expression was seen in the
exocrine tissue.
Despite the active expression of gastrin in the postnatal pancreas, there was no
obvious stimulation ofislet-cellgrowth in INS-GAS 1 mice over that ofcontrols. This
fact was confirmed by point-counting morphometrics of pancreatic tissue from
age-matched INS-GAS 1 and control mice, which showed no difference in islet-cell
mass between INS-GAS transgenic and control mice (Fig. 4). Thus the sustained
expression of gastrin in the postnatal pancreas alone is insufficient to stimulate
islet-cell growth.
Islet cells develop from committed islet precursors, which proliferate and bud
from the fetal pancreatic ducts [5]. Since these ductal islet-cell precursors disappear
afterbirth, absence ofthese precursor cells in the postnatal pancreasmayexplain the
failure of gastrin to stimulate islet growth in the INS-GAS transgenic mice. Conse-
quently, an effect of transgenic gastrin expression may only be seen in mice which
have persistence ofislet precursors. For this reason, INS-GAS mice were matedwith
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FIG. 4. Effect of insulin-gastrin and metallothionein-TGFa transgene expression
on ductular and islet mass, compared to wild-type mice. Islet and duct mass were
determined by point-counting morphometrics ofpancreatic sections from six or more
mice. Duct mass was markedly(+ ++) increased in TGFasingle transgenics, butonly
slightly (+) increased in INS-GAS/TGFa double transgenics. Islet mass was signifi-
cantly (++) increased in the INS-GAS/TGFa double transgenics, but notchanged in
INS-GAS and TGFa single transgenics.
metallothionein-transforming growth factor a (MT-TGFa) transgenic mice which
have pancreatic TGFa overexpression from a metallothionein promoter-human
TGFa cDNA transgene [17-19]. Adult MT-TGFa transgenic mice have pancreatic
changes resembling the proliferating ductules of the developing pancreas, which
contain islet and exocrine precursor cells. TGFa causes numerous foci ofmetaplastic
ductules in the MT-TGFa pancreas, which represent focally redirected differentia-
tion ofpancreatic epithelial cells. These metaplastic ducts have cells immunoreactive
for amylase, indicating that acinar cell differentiation occurswithin these metaplastic
ductules [18].
To determine whether these metaplastic ductules also contain islet precursors,
metaplastic ducts from MT-TGFa pancreas were examined immunohistochemically
for insulin immunoreactivity. These studies showed that the metaplastic ductules
contain insulin-expressing cells, indicating that differentiation along the islet lineage
occurs within the metaplastic ducts [13]. Although TGFa-induced metaplastic ducts
contain islet precursor cells, point-counting morphometrics indicated no increase in
islet-cell mass of MT-TGFa mice, even though there was a greater than tenfold
increase in pancreatic ductules (Fig. 4).
The effect of persistent pancreatic gastrin expression was examined in TGFa-
induced metaplastic pancreas by crossing the homozygous MT-TGFa (MT-42) line
with the heterozygous INS-GAS transgenic line. The offspring of this cross were
either heterozygotic MT-TGFa single transgenics (TGFa+) or double transgenics
containing both INS-GAS and MT-TGFa transgenes (INS-GAS+/TGFa+). Age-
matched wild-type mice with a similar genetic background were used as controls. All
three groups of mice were placed on 50 mM ZnCl2 (which induces the mouse
metallothionein promoter) at three weeks of age.
At four months of age, the animals were sacrificed and the pancreas removed. The
gross morphological appearance of the pancreas from the MT-TGFa and the
INS-GAS/MT-TGFa mice were similar in being uniformly rigid and whitish in
normal normal +++ +
increased increased
normal normal normal ++
increased
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appearance in both lines. There was, however, a striking difference in the pancreatic
histologybetween theTGFa transgenic and the INS-GAS/TGFa double transgenics
[13]. The pancreas from the MT-TGFa x FVB mouse had the typical interstitial
fibrosis and florid ductular metaplasia, similar to changes previously described
[19-21] compared to the pancreas from the wild-type control. In contrast, the
pancreas from the INS-GAS/MT-TGFa mice exhibited a histology that resembled
that of the control pancreas more than that of the MT-TGFt mice. Thus, gastrin
overexpression in the postnatal pancreas reduced the ductular metaplasia caused by
TGFa overexpression. This result was confirmed byquantitatingpancreatic ductular
mass by point-counting morphometrics in the three groups ofmice. The TGFa mice
had a markedly increased ductularmass compared to controls (Fig. 4). Expression of
the gastrin transgene in the INS-GAS/TGFao mice markedly reduced the TGFao-
inducedincrease in ductal cell mass, although the ductal masswasstill increased over
controlvalues.
Co-expression ofgastrin and TGFa in the INS-GAS/TGFa pancreas also signifi-
cantly increased the islet mass compared to controls, in contrast to the ineffective-
ness ofTGFa and gastrin expression alone (Fig. 4). The islet mass ofthe INS-GAS/
MT-TGFot double transgenics was significantly (twofold) greater than the islet mass
ofthe control mice, whereas the islet-cell mass ofthe MT-TGFa transgenics did not
differ significantly from controls [13]. Since gastrin decreased the metaplastic duct
mass, the increase in islet mass may result from gastrin inducing differentiation of
insulin-positive cells in the TGFa-induced metaplastic ductules.
The differences in pancreatic morphology between the TGFa mice and the
INS-GAS/MT-TGFa mice were not due to decreased levels of pancreatic TGFa
expression in the INS-GAS/MT-TGFa mice. Northern blot analysis showed equiva-
lent expression; furthermore, TGFa radioimmunoassay also demonstrated equiva-
lent levels of TGFaL immunoreactivity in pancreatic extracts from the MT-TGFa
mice and INS-GAS/MT-TGFa double transgenic mice [13].
These synergistic effects of gastrin and TGFa transgene expression on islet
development in the adult pancreas may elucidate part of the regulation of islet
differentiation in the normal fetal pancreas. The pancreatic islets develop from
endodermal stem cells that lie in the fetal pancreatic ducts, which also contain stem
cells that differentiate into the exocrine pancreas. The development of the islets
during the fetal period proceeds through a number of discrete stages that are
regulated by peptide growth factors. Since TGFa is expressed in fetal pancreatic
ducts [22], TGFa may stimulate proliferation ofprotodifferentiated islet precursors
as in the postnatal TGFa transgenic pancreas. TGFa overexpression alone cannot,
however, effect transition of the protodifferentiated islet precursors into fully
differentiated islets. The increase in islet mass seen in the double (INS-GAS+/
TGFa+) transgenic mice suggests that gastrin may have an analogous role during
fetal development, when the endogenous gastrin gene is transiently expressed in the
fetal pancreas, and may be one of the factors responsible for the transition of islet
precursors into mature islet cells. The cellular mechanisms responsible for the
synergistic interaction between TGFa andgastrin onislet formation are unknown. In
addition, other peptide growth factors that are expressed in fetal life may also be
required for normal islet development. These transgenic studies indicate, however,
that islet growth can be stimulated by local expression of two growth factors, gastrin
and TGFa.
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